vs
Side-by-side financial comparison of DULUTH HOLDINGS INC. (DLTH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $114.9M, roughly 1.5× DULUTH HOLDINGS INC.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -8.8%, a 10.4% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -9.6%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -31.6%).
Duluth Holdings Inc., which primarily sells goods through its Duluth Trading Company brand, is an American workwear and accessories company.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DLTH vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $114.9M | $177.4M |
| Net Profit | $-10.1M | $2.9M |
| Gross Margin | 53.8% | — |
| Operating Margin | -7.7% | 3.9% |
| Net Margin | -8.8% | 1.6% |
| Revenue YoY | -9.6% | 5.0% |
| Net Profit YoY | 64.6% | — |
| EPS (diluted) | $-0.29 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $114.9M | $196.9M | ||
| Q3 25 | $131.7M | $179.5M | ||
| Q2 25 | $102.7M | $181.1M | ||
| Q1 25 | $241.3M | $168.9M | ||
| Q4 24 | $127.1M | $187.3M | ||
| Q3 24 | $141.6M | $168.6M | ||
| Q2 24 | $116.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-10.1M | — | ||
| Q3 25 | $1.3M | $5.4M | ||
| Q2 25 | $-15.3M | $-4.8M | ||
| Q1 25 | $-5.6M | $4.8M | ||
| Q4 24 | $-28.2M | — | ||
| Q3 24 | $-2.0M | $-143.5M | ||
| Q2 24 | $-7.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 53.8% | 79.5% | ||
| Q3 25 | 54.7% | 80.9% | ||
| Q2 25 | 52.0% | 77.4% | ||
| Q1 25 | 44.1% | 79.7% | ||
| Q4 24 | 52.3% | 78.7% | ||
| Q3 24 | 52.3% | 76.9% | ||
| Q2 24 | 52.8% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -7.7% | 1.2% | ||
| Q3 25 | 1.8% | 3.5% | ||
| Q2 25 | -12.0% | 4.7% | ||
| Q1 25 | -1.8% | 1.2% | ||
| Q4 24 | -17.4% | 13.2% | ||
| Q3 24 | -1.1% | -82.8% | ||
| Q2 24 | -7.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -8.8% | — | ||
| Q3 25 | 1.0% | 3.0% | ||
| Q2 25 | -14.9% | -2.7% | ||
| Q1 25 | -2.3% | 2.8% | ||
| Q4 24 | -22.2% | — | ||
| Q3 24 | -1.4% | -85.1% | ||
| Q2 24 | -6.7% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.29 | $0.05 | ||
| Q3 25 | $0.04 | $0.12 | ||
| Q2 25 | $-0.45 | $-0.11 | ||
| Q1 25 | $-0.17 | $0.10 | ||
| Q4 24 | $-0.84 | $0.38 | ||
| Q3 24 | $-0.06 | $-3.11 | ||
| Q2 24 | $-0.24 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.2M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $160.6M | $653.9M |
| Total Assets | $468.0M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $8.2M | $238.4M | ||
| Q3 25 | $5.7M | $246.3M | ||
| Q2 25 | $8.6M | $445.9M | ||
| Q1 25 | $3.3M | $493.6M | ||
| Q4 24 | $9.3M | $484.6M | ||
| Q3 24 | $9.8M | $453.8M | ||
| Q2 24 | $6.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $160.6M | $693.1M | ||
| Q3 25 | $170.0M | $727.2M | ||
| Q2 25 | $167.9M | $757.8M | ||
| Q1 25 | $182.7M | $798.5M | ||
| Q4 24 | $188.1M | $778.3M | ||
| Q3 24 | $215.7M | $749.6M | ||
| Q2 24 | $218.4M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $468.0M | $1.3B | ||
| Q3 25 | $433.8M | $1.3B | ||
| Q2 25 | $463.7M | $1.5B | ||
| Q1 25 | $452.4M | $1.6B | ||
| Q4 24 | $533.1M | $1.6B | ||
| Q3 24 | $488.6M | $1.5B | ||
| Q2 24 | $471.4M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.7M | — |
| Free Cash FlowOCF − Capex | $-8.9M | — |
| FCF MarginFCF / Revenue | -7.8% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-6.7M | $43.7M | ||
| Q3 25 | $32.0M | $60.8M | ||
| Q2 25 | $-56.5M | $12.0M | ||
| Q1 25 | $41.2M | $35.5M | ||
| Q4 24 | $-41.1M | $33.1M | ||
| Q3 24 | $16.6M | $53.9M | ||
| Q2 24 | $-33.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-8.9M | $43.5M | ||
| Q3 25 | $29.8M | $57.0M | ||
| Q2 25 | $-57.8M | $9.3M | ||
| Q1 25 | $38.7M | $26.9M | ||
| Q4 24 | $-43.7M | $31.0M | ||
| Q3 24 | $15.0M | $49.8M | ||
| Q2 24 | $-35.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -7.8% | 22.1% | ||
| Q3 25 | 22.6% | 31.7% | ||
| Q2 25 | -56.3% | 5.1% | ||
| Q1 25 | 16.0% | 15.9% | ||
| Q4 24 | -34.4% | 16.6% | ||
| Q3 24 | 10.6% | 29.6% | ||
| Q2 24 | -30.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 0.1% | ||
| Q3 25 | 1.7% | 2.2% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 1.0% | 5.1% | ||
| Q4 24 | 2.1% | 1.1% | ||
| Q3 24 | 1.2% | 2.4% | ||
| Q2 24 | 1.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 25.40× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLTH
| Sales Channel Directly To Consumer | $67.4M | 59% |
| Sales Channel Through Intermediary | $47.4M | 41% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
